CEO David Endicott will present at the 2026 J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 8:15 a.m. PST.

Alcon Inc.'s acquisition of LENSAR, Inc. remains pending, with an FTC antitrust review likely delaying the closing. Learn ...

A fourth delay hits Staar Surgical’s shareholder vote on Alcon's $1.6B takeover as Broadwood Partners calls the deal flawed ...

STAAR Surgical Company (NASDAQ: STAA), the manufacturer of the Implantable Collamer® Lens (ICL) today announced that Alcon (SIX/NYSE: ALC) has exercised its right under the Alcon merger agreement to ...

Alcon has experienced robust Q1 growth, driven by double-digit growth in vision care, particularly in the contact lens market. The company's strong revenue growth is attributed to successful product ...

Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...

Alcon, an international eye care company with facilities in Berks County, has announced it plans to acquire STAAR Surgical Co. Under the terms of the agreement announced Tuesday, Alcon will purchase ...

Adds STAAR Surgical comment. STAAR Surgical (STAA) dropped 5% after proxy adviser Glass Lewis recommended holders reject the revised $30.75 a share offer from Alcon (ALC). “We do not believe there ...

Alcon’s $770 million takeover of Aerie Pharmaceuticals has delivered an early win. The lead candidate in the acquired pipeline met the primary endpoint in a pair of phase 3 dry eye trials, positioning ...

Former Novartis subsidiary Alcon, after targeting the pharmaceutical eye drop scene with a trio of recent drug purchases, is adding another pair of arrows to its ophthalmic quiver. And this time, the ...

Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, and STAAR Surgical Company (NASDAQ: STAA), the manufacturer of the Implantable Collamer® Lens (ICL), ...

The series Point Break is set 35 years after the events of the original film and comes from David Kalstein and Alcon Entertainment.